### Scientific program

**Monday 14 October 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30-08:10</td>
<td><strong>Masterclasses</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prematurity prevention: from ultrasound to proteomics</td>
<td>Convention Hall I (C)</td>
</tr>
<tr>
<td></td>
<td>R. Romero (United States)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Malformations of cortical development: is it possible to reach an etiologic diagnosis?</td>
<td>Convention Hall II</td>
</tr>
<tr>
<td></td>
<td>G. Malinger (Israel); D. Prayer (Austria)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>How to evaluate a patient presenting with infertility with a single scan</td>
<td>Convention Hall I (D)</td>
</tr>
<tr>
<td></td>
<td>B.R. Benacerraf (United States)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ultrasound and cfDNA: a happy marriage?</td>
<td>Estrel Hall (A+B)</td>
</tr>
<tr>
<td></td>
<td>C.M. Bilardo (Netherlands); F. Grati (Italy)</td>
<td></td>
</tr>
<tr>
<td>08:15-09:35</td>
<td><strong>cfDNA in our daily practice: what should we expect?</strong></td>
<td>Convention Hall I (C)</td>
</tr>
<tr>
<td>08:15</td>
<td><strong>INVITED</strong> Title TBC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>L. Chitty (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>08:45</td>
<td><strong>OC02.01</strong> Performance of first trimester screening for Trisomy 21 in twin pregnancies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>E. Bergstrand-Poulsen (Denmark)</td>
<td></td>
</tr>
<tr>
<td>08:50</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>08:53</td>
<td><strong>OC02.02</strong> Performance of a genome-wide PCR-free, paired-end sequencing-based non-invasive prenatal screening test, VeriSeq NIPT Solution v2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. Bhatt (United States)</td>
<td></td>
</tr>
<tr>
<td>08:58</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>09:01</td>
<td><strong>OC02.03</strong> Predictive value of cell-free DNA screening in a modern cohort: a single institution's experience</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D.L. Gray (United States)</td>
<td></td>
</tr>
<tr>
<td>09:06</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>09:09</td>
<td><strong>OC02.04</strong> Residual risk for a postnatal diagnosis and livebirth of an atypical chromosomal aberration following first trimester combined screening</td>
<td></td>
</tr>
<tr>
<td></td>
<td>P. Conner (Sweden)</td>
<td></td>
</tr>
</tbody>
</table>

*This is the preliminary program and is subject to change*
09:14  Discussion

09:17  **OC02.05** What is the chance for pathogenic chromosomal microarray analysis results in structurally normal fetuses?  
*H. Daum (Israel)*

09:22  Discussion

09:25  **OC02.06** Prenatal fetal gender discordance following cfDNA testing  
*J. Miguelez (Brazil)*

09:30  Discussion

**08:15-09:35**  
**Cerebellum and posterior fossa**  
*Chairs: B.R. Benacerraf (United States); K. Karl (Germany)*  

08:15  **LIVE SCAN** How I scan the brain [industry supported]  
*L. Guibaud (France)*

08:35  **OC03.01** Prenatal diagnosis of rhombencephalosynapsis: beyond the fusion of the cerebellar hemispheres  
*K.K. Haratz (Israel)*

08:40  Discussion

08:43  **OC03.02** 3D fetal MRI visualisation of cerebellar white matter tracts  
*G.O. Dovjak (Austria)*

08:48  Discussion

08:51  **OC03.03** Neurodevelopmental outcome of children with fetal isolated vermian abnormalities  
*R. Berkovitz-Shperling (Israel)*

08:56  Discussion

08:59  **OC03.04** Prospective detection and differential diagnosis of cystic posterior fossa anomalies by assessing posterior brain at 11–14 weeks  
*T. Fanelli (Italy)*

09:04  Discussion

09:07  **OC03.05** Cerebellar hypoplasia: prenatal diagnosis and outcome  
*T. Borkowski (Israel)*

09:12  Discussion
09:15  **OC03.06** Diagnosis of spina bifida in a routine clinical setting at the first trimester scan: a prospective multicentre study  
*J. Tiechl (Austria)*

09:20  Discussion

09:23  **OC03.07** Prenatal diagnosis of malformations of cortical development associated to midbrain-hindbrain anomalies  
*K.K. Haratz (Israel)*

09:28  Discussion

**08:15-09:35** Classifying and managing ovarian masses  
*Chairs: T. Bourne (United Kingdom); D. Timmerman (Belgium)*

08:15  **INVITED** Using the IOTA ADNEX model to classify all ovarian masses  
*W. Froyman (Belgium)*

08:35  **OC04.01** Imaging in gynecology: mature cystic teratoma of the ovary  
*R. Heremans (Belgium)*

08:40  Discussion

08:43  **OC04.02** The role of IOTA ADNEX model compared to subjective assessment in the preoperative diagnosis of unilocular-solid adnexal masses  
*D. Franchi (Italy)*

08:48  Discussion

08:51  **OC04.03** Prediction of adnexal torsion by ultrasound in women with acute abdominal pain  
*R. Bardin (Israel)*

08:56  Discussion

08:59  **OC04.04** A machine-learning algorithm to distinguish benign and malignant adnexal tumours from ultrasound images  
*D. Al-Karawi (United Kingdom)*

09:04  Discussion

09:07  **OC04.05** Conservative management of adnexal pathology classified as benign by ADNEX model before and after the menopause: a prospective multicentre study  
*S. Rodrigues (Portugal)*

09:12  Discussion

This is the preliminary program and is subject to change
09:15  **OC04.06** Management of adnexal masses during pregnancy: a prospective study  
C. Landolfo (United Kingdom)

09:20  Discussion

09:23  **OC04.07** Presurgical assessment of adnexal masses: performance of IOTA-LR2, ADNEX and RMI models and added value of tumour marker-based models ROMA and CPH-I  
N. Carreras Diéguez (Spain)

09:28  Discussion

**08:15-09:35** Ultrasound in the labour ward  
Estrel Hall (A+B)

08:15  **ISUOG GUIDELINES** Intrapartum ultrasound  
T. Ghi (Italy)

08:35  **OC05.01** Rotational forceps delivery: a novel role of intrapartum ultrasound for quality control and teaching  
L. Hinkson (Germany)

08:40  Discussion

08:43  **OC05.02** Movement of the fetal head during active pushing assessed with ultrasound  
B.H. Kahrs (Norway)

08:48  Discussion

08:51  **OC05.03** Ultrasound in the second stage of labour before instrumental vaginal delivery: a randomised controlled trial  
J. Barros (Portugal)

08:56  Discussion

08:59  **OC05.04** Dynamic two-dimensional transperineal ultrasound prior to perineal suturing as a screening tool for anal sphincter injury and fecal incontinence  
G. Salsi (Italy)

09:04  Discussion

09:07  **OC05.05** Moulding of the fetal head diagnosed with ultrasound  
T.M. Eggebø (Norway)

09:12  Discussion

*This is the preliminary program and is subject to change*
09:15  **OC05.06** Point of Care Ultrasound for fluid assessment and management in a pre-eclamptic patient with postpartum hemorrhage  
*S. Lau (Hong Kong)*

09:20  Discussion

09:23  **OC05.07** Prediction of mode of delivery using intrapartum ultrasound in the assessment of fetal head deflexion  
*F. Bellussi (Italy)*

09:28  Discussion

09:40-10:20  **Short oral presentations (OP)**

**OP01** Novel imaging methods, artificial intelligence and more  
*Chairs: C. Brezinka (Austria); J. Stirnemann (France)*

**OP02** Multimodal management of fetal anomalies  
*Chairs: P. Acharya (India); A. Diemert (Germany)*

**OP03** Classifying and managing ovarian masses  
*Chairs: J. Preisler (Chile); S. Saso (United Kingdom)*

**OP04** Ultrasound in the labour ward  
*Chairs: K. Kalache (Qatar); C. Bamberg (Germany)*

10:15-10:45  **Coffee and e-poster viewing**

10:45-12:05  **New genetic technologies: how can they help?**  
*Chairs: P. Benn (United States); F. Grati (Italy)*

10:45  **INVITED** Cases that stump me  
*L. Dugoff (United States)*

11:05  **OC06.01** Single gene, gene panel and exome sequencing applied in structurally abnormal fetuses with a normal chromosomal microarray analysis  
*A. Borrell (Spain)*

11:10  Discussion

11:13  **OC06.02** A new molecular work-up for early pregnancy losses based on QF-PCR and SNP-array in chorionic villi is more accurate than karyotyping  
*L. Benitez Quintanilla (Spain)*

11:18  Discussion

11:21  **OC06.03** Increased fetal nuchal translucency: genetic examination by the advanced technology  
*M. Chen (China)*

---

This is the preliminary program and is subject to change
11:26 Discussion

11:29 **OC06.04** Population-based prevalence of 22q11 deletion syndrome and other chromosome abnormalities in a combined prenatal and postnatal cohort

*L. Hui (Australia)*

11:34 Discussion

11:37 **OC06.05** Prenatal diagnosis and clinical analysis of CNV in fetal cleft lip

*X. Chen (China)*

11:42 Discussion

11:45 **OC06.06** Cell-free DNA in the detection of chromosomal aneuploidies in early fetal demise and miscarriage

*M. Hynek (Czech Republic)*

11:50 Discussion

11:53 **OC06.07** Maternal plasma genome-wide cell-free DNA testing can detect fetal aneuploidy in pregnancy loss and can be used to guide further work-up in recurrent losses

*A. Borrell (Spain)*

11:58 Discussion

10:45-12:05 **The challenge of ventriculomegaly**

*Consortium Hall II*

**Chairs:** G. Malinger (Israel); R. Chaoui (Germany)

10:45 **INVITED** Fetal brain anomalies: how to counsel your patient

*A. T. Papageorghiou (United Kingdom)*

11:05 **OC07.01** Role of prenatal magnetic resonance imaging in fetuses with isolated ventriculomegaly: a multicentre study

*D. Di Mascio (Italy)*

11:10 Discussion

11:13 **OC07.02** Differential diagnosis of irregular lateral ventricle walls: correlation between prenatal imaging and fetal neuropathological studies

*K.K. Haratz (Israel)*

11:18 Discussion

11:21 **OC07.03** Prenatal work-up, associated anomalies and long-term postnatal outcomes of fetuses with 9–10mm cerebral ventricular atria width

*M. Sharon-Weiner (Israel)*

*This is the preliminary program and is subject to change*
11:26  Discussion

11:29  **OC07.04** Differential regional distribution of ventricular volumes in fetuses with isolated non-severe ventriculomegaly is associated with poor neurodevelopmental outcome  
*N.M. Hahner (Spain)*

11:34  Discussion

11:37  **OC07.05** Prenatal diagnosis of arachnoid cysts: MRI features and neurodevelopmental outcome  
*E. Katorza (Israel)*

11:42  Discussion

11:45  **OC07.06** Prenatal diagnosis of dural sinus malformation using fetal magnetic resonance imaging  
*D. Prayor (Austria)*

11:50  Discussion

11:53  **OC07.07** SS-FSE FAIR ASL parameters for non-invasive measurement of fetal brain perfusion *in vivo*  
*A.E. Millicher (France)*

11:58  Discussion

10:45-12:05  **Investigating women with abnormal bleeding**  
*Chairs: J. Huirne (Netherlands); L. Jokubkiene (Sweden)*  

10:45  **INVITED** Predicting pathology in women with abnormal bleeding using standardised ultrasound features: data from the IETA 1 study on >3,000 women  
*T. Van den Bosch (Belgium)*

11:00  **INVITED** Caesarean section scars (the niche): ultrasound assessment and the current position on whether treatment is necessary  
*J. Huirne (Netherlands)*

11:15  **OC08.01** Could comparative elastography help in the sonographic diagnosis of adenomyosis?  
*S. Iglesias Ferreira (Spain)*

11:20  Discussion

11:23  **OC08.02** A prospective controlled study for Caesarean section niche development with hysteroscopic correlation in symptomatising patients  
*H.M. Gaafer (Egypt)*

---

This is the preliminary program and is subject to change
11:28  Discussion

11:31  **OC08.03** Prevalence of malignancy or premalignancy in postmenopausal women without vaginal bleeding in whom the endometrial thickness measured ≥11mm
*M. Wong (United Kingdom)*

11:36  Discussion

11:39  **OC08.04** Oral administration of norethisterone acetate in women with adenomyosis: effects on ultrasound features and clinical symptoms
*L. Lazzeri (Italy)*

11:44  Discussion

11:47  **OC08.05** Incidental finding of endometrial polyps: results from a prospective multicentre study (IETA3)
*R. Heremans (Belgium)*

11:52  Discussion

11:55  **OC08.06** Ability to adequately visualise an endometrial echo on transvaginal ultrasound in asymptomatic postmenopausal women
*S. R. Goldstein; A. Khafaga (United States)*

12:00  Discussion

10:45-12:05  **Prediction of pregnancy complications**
*Estrel Hall (A+B)*

10:45  **INVITED** Prediction of pre-eclampsia in 2019
*D.L. Rolnik (Australia)*

11:05  **OC09.01** Prediction of preterm delivery by cervical length at 11–14 weeks of gestation
*M. Bermudez Rojas (Mexico)*

11:10  Discussion

11:13  **OC09.02** The risk of subsequent preterm birth in women with a short cervix who delivered at term
*J. Wie (Republic of Korea)*

11:18  Discussion

11:21  **OC09.03** Contribution of the amniocentesis for the ultrasound prediction of spontaneous preterm delivery in women with preterm labour
*C. Murillo Bravo (Spain)*
11:26 Discussion

11:29 **OC09.04** A rapid MMP-8 bedside test performs better than amniotic fluid white blood cell count in the antenatal identification of acute histologic chorioamnionitis
*S. Hong (Republic of Korea)*

11:34 Discussion

11:37 **OC09.05** Low Papp-A at booking: is serial ultrasound surveillance warranted?
*A. Anness (United Kingdom)*

11:42 Discussion

11:45 **OC09.06** Value of universal third trimester ultrasonography as predictor of adverse perinatal outcome at term
*A. Cavallaro (United Kingdom)*

11:50 Discussion

11:53 **OC09.07** Women with a second trimester placenta previa of 14mm or less are at low risk of a placenta previa in the third trimester: a prospective cohort
*C.H. Jansen (Netherlands)*

11:58 Discussion

12:10-12:50 **Short oral presentations (OP)**

**OP05** Issues in prenatal genetic testing
*Chairs: P. Benn (United States); P. Kozlowski (Germany)*

**OP06** Fetal renal abnormalities
*Chairs: R. Ruano (United States); A. Geipel (Germany)*

**OP07** Investigating causes of abnormal uterine bleeding and uterine disease
*Chairs: E. Epstein (Sweden); T. Van den Bosch (Belgium)*

**OP08** Prediction of pregnancy complications
*Chairs: L. Poon (Hong Kong); J. Stone (United States)*

Convention Hall I (C)

12:45-14:15 **Lunch and e-poster viewing**

13:00-14:00 **Industry sponsored satellite symposia**

14:15-15:35 **Novel developments in our field**
*Chairs: L.J. Salomon (France); K. Maršál (Sweden)*

Convention Hall I (C)

This is the preliminary program and is subject to change
14:15  **INVITED** Imaging the future: overview of latest new developments in fetal imaging, simulation, AI  
       H. Werner (Brazil)

14:30  **OC10.01** Combination of ultrasound and magnetic resonance imaging for virtual reality systems to evaluate fetal malformations  
       H. Werner (Brazil)

14:35  Discussion

14:38  **OC10.02** Bioeffects safety indices of ultrasound: quantifying adherence to recommendations on routine obstetric scan  
       L. Drukker (United Kingdom)

14:43  Discussion

14:46  **OC10.03** Fetal exposure to magnetic resonance imaging: neurodevelopment outcome  
       E. Katorza (Israel)

14:51  Discussion

14:54  **OC10.04** Introducing ISUOG's Basic Training novel approach to the second trimester anomaly scan: the 20+2 planes  
       T. Chudleigh (United Kingdom)

14:59  Discussion

15:02  **OC10.05** The "Valensise Radar" to understand the maternal hemodynamic status  
       D. Farsetti (Italy)

15:07  Discussion

15:10  **OC10.06** Breaking bad news due to fetal abnormalities during prenatal ultrasound examination: can simulation training be done?  
       E. Mousty (France)

15:15  Discussion

15:18  **OC10.07** To measure or not to measure? Current NCHD practice of abdominal circumference measurement in the Antenatal Clinic, Cork University Maternity Hospital, and the level of training required in achieving international best practice  
       S. O'Brien (Republic of Ireland)

15:23  Discussion

This is the preliminary program and is subject to change
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:26</td>
<td>OC10.08</td>
<td>A standardised examination protocol based on priority assessment levels to optimise first trimester ultrasound screening</td>
<td>France</td>
</tr>
<tr>
<td>15:31</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:15</td>
<td>14:15-15:35</td>
<td>Fetal anomalies: head and spine</td>
<td>United States; Netherlands</td>
</tr>
<tr>
<td>14:15</td>
<td>LIVE SCAN</td>
<td>Fetal anomalies head to toe [industry supported]</td>
<td>Netherlands</td>
</tr>
<tr>
<td>14:35</td>
<td>OC11.01</td>
<td>Sensitivity of retronasal triangle view in first trimester detection of palatine clefts</td>
<td>India</td>
</tr>
<tr>
<td>14:40</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:43</td>
<td>OC11.02</td>
<td>Characterisation of the fetal external ear location and size by three-dimensional ultrasound</td>
<td>Israel</td>
</tr>
<tr>
<td>14:48</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:51</td>
<td>OC11.03</td>
<td>The relevance of fetal ductus venosus or ductus venosus-like structures-inferior vena cava shunt abnormalities and Down's syndrome</td>
<td>China</td>
</tr>
<tr>
<td>14:56</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:59</td>
<td>OC11.04 &amp; OC11.05</td>
<td>Vertebral patterns in conditions with variable outcome</td>
<td>Netherlands</td>
</tr>
<tr>
<td>15:07</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:10</td>
<td>OC11.06</td>
<td>Role of early ultrasound scan: a two-year study of cases of increased nuchal translucency with normal karyotype</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>15:15</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:18</td>
<td>OC11.07</td>
<td>Randomised controlled study on the use of systematic simulator-based training (OPUS Fetal Heart Trainer) for learning the standard heart planes in fetal echocardiography</td>
<td>Germany</td>
</tr>
<tr>
<td>15:23</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
15:26 **OC11.08** Syndromic craniofacial dysmorphic feature assessment *in utero*: potential for a novel imaging methodology with reconstructed 3D fetal MRI models  
*J. Matthew* (United Kingdom)

15:31 Discussion

14:15-15:35 **Ultrasound to help manage the oncology patient**  
*Chairs: A.C. Testa* (Italy); *D. Fischerová* (Czech Republic)

14:15 **INVITED** How does imaging influence my management of women with probable ovarian carcinoma  
*C. Fotopoulou* (United Kingdom)

14:35 **INVITED** How to assess the extent of tumour for women with endometrial and cervical cancer  
*E. Epstein* (Sweden)

14:49 **INVITED** Preoperative assessment of ovarian cancer  
*D. Fischerová* (Czech Republic)

15:03 **OC12.01** Can ultrasound do distinguished diagnosis between complete and partial hydatidiform mole with coexistent fetus?  
*J. Qin* (China)

15:08 Discussion

15:11 **OC12.02** Management of borderline ovarian tumours: overall survival and long-term follow-up  
*S. Saso* (United Kingdom)

15:16 Discussion

15:19 **OC12.03** Comparison of clinical and ultrasound characteristics in low- and high-grade serous cancer  
*B. Cornelli* (Italy)

15:24 Discussion

15:27 **OC12.04** A new advanced tool in gynecological surgery: the intraoperative ultrasound examination  
*I. De Blasis* (Italy)

15:32 Discussion

14:15-15:35 **Fetal interventions in monochorionic twins**  
*Chairs: E. Gratacós* (Spain); *K. Hecher* (Germany)

This is the preliminary program and is subject to change
14:15 **VIDEO**: Fetoscopic surgery of monochorionic twins  
A. Johnson (United States)

14:31 **OC13.01** Surgical versus expectant management in twin reversed arterial perfusion sequence  
K. Kostyukov (Russian Federation)

14:36 Discussion

14:39 **OC13.02** Umbilical artery end-diastolic flow patterns are associated with right ventricular outflow abnormalities in Twin–twin transfusion syndrome  
J. Espinoza (United States)

14:44 Discussion

14:47 **OC13.03** Perioperative hemodynamic changes in Twin–twin transfusion syndrome and long-term neurodevelopmental outcomes  
M. Gijtenbeek (Netherlands)

14:52 Discussion

14:55 **OC13.04** Intertwin differences in fetal cardiac geometry are associated with decreased dual twin survival in Twin–twin transfusion syndrome  
R. Corroenne (United States)

15:00 Discussion

15:03 **OC13.05** Cervical pessary for prevention of preterm birth in Twin–twin transfusion syndrome  
J. Gottula (United States)

15:08 Discussion

15:11 **OC13.06** Risk of intraterine demise of donors with selective fetal growth restriction after laser surgery for Twin–twin transfusion syndrome  
J. Ortiz (Germany)

15:16 Discussion

15:19 **OC13.07** Ultrasound evaluation of fetomaternal circulation after modified laparoscopic cervicoisthmic cerclage  
K. Seo (Japan)

15:24 Discussion

15:27 **OC13.08** Mechanical properties and toxicity of different bioadhesives as sealing system for fetal membranes  
T. Micheletti (Spain)

This is the preliminary program and is subject to change
15:32 Discussion

15:35-16:00 Coffee and e-poster viewing

16:00-17:30 Workshop

**How isolated is “isolated” corpus callosum agenesis?**

*Convention Hall I (C)*

16:00 The contribution of ultrasound to the diagnosis of associated anomalies

*D. Pugash (Canada)*

16:25 The contribution of MRI to the diagnosis of associated anomalies

*A. E. Millischer (France)*

16:50 Is this corpus callosum normal?

*G. Malinger (Israel)*

17:15 Discussion

16:00-17:30 Workshop

**Abnormalities of situs and the venous system**

*Convention Hall II*

16:00 **LIVE SCAN** Assessing situs and the venous system [industry supported]

*J. Carvalho (United Kingdom)*

16:20 Fetal umbilico portal ductus venous system

*R. Achiron (Israel)*

16:40 Pulmonary venous system

*D. Paladini (Italy)*

17:00 Fetal situs anomalies and heterotaxy

*R. Chaoui (Germany)*

17:20 Discussion

16:00-17:30 Workshop

**Classifying ovarian tumours: knowing how to classify ovarian masses using IOTA terminology, rules and models**

*Convention Hall I (D)*

16:00 Terms and definitions used to describe ovarian masses: the key to getting it right

*J. Preisler (Chile)*

16:15 IOTA descriptors and simple rules: what are the ultrasound features and how to use the rules – can they be applied to all masses?

*T. Bourne (United Kingdom)*

This is the preliminary program and is subject to change
16:30  The IOTA ADNEX model: what variables are used and how to interpret the results  
D. Timmerman (Belgium)

16:45  How worried should you be by solid projections into otherwise unilocular looking cysts?  
C. Landolfo (United Kingdom)

17:00  Using the IOTA approach to classify ovarian masses in clinical practice: case examples  
W. Froyman (Belgium)

16:00-17:30  Workshop: Assessing early fetal growth restriction  
Estrel Hall (A+B)

16:00  Assessing fetal growth: the ISUOG fetal biometry guidelines  
L. J. Salomon (France)

16:20  Pathophysiology of early onset fetal growth restriction  
A. A. Baschat (United States)

16:40  Management of early growth restriction: the European view  
E. Gratacós (Spain)

16:55  Management of early growth restriction: the USA view  
A. Abuhamad (United States)

17:10  Discussion

16:00-17:30  Workshop  
3D ultrasound of the fetal head  
Estrel Hall (C4)  

16:00  Volume acquisition and qualitative and quantitative analysis of the fetal face and skull: a step-by-step guide  
B. Tutschek (Switzerland)

16:20  Genetic syndromes with an abnormal face that you must know: added value of 3D  
E. Merz (Germany)

16:40  Brain views that benefit from or are only possible with 3D  
A. Youssef (Italy)

17:00  Live volume/video demonstration face and skull:  
1. essentials in 2D and additional information from 3D; 2. bone rendering  
B. Benoit (France)

17:20  Discussion
29th World Congress on Ultrasound in Obstetrics and Gynecology
12-16 October 2019, Berlin, Germany

Hubs

08:15-09:15 Interactive Hubs
ISUOG Basic Training series I
Chair: R. Abu-Rustum (United States)

In conversation with I.E. Timor-Tritsch: Caesarean scar pregnancy

In conversation with S. Campbell: pearls of gynecological imaging

09:40-10:20 Poster discussions (P)
P01: cfDNA and new genetic technologies
Chair: A. Sotiriadis (Greece)
P02: Diagnosis and prognosis of congenital heart defects
Chair: B. Tutschek (Switzerland)
P03: Ultrasound and reproductive medicine
Chairs: W.P. Martins (Brazil); M. Leonardi (Australia)
P04: Fetal disease I
Chair: N. Vrachnis (Greece)

10:45-11:45 Interactive Hubs
Outreach virtual mentor workshop
Chair: L. Hanson (United States)

Infections Chair: TBC

In conversation with G. Condous: how I evaluate my patients for endometriosis before surgery
Chairs: G. Hudelist (Austria); N. Raine-Fenning (United Kingdom)

12:10-12:50 Poster discussions (P)
P05: Fetal disease II
Chairs: S.C. Westerway (Australia); A. Khurana (India)
P06: Fetal growth: predicting outcomes
Chairs: P. Glanc (Canada); R. Cruz-Martinez (Mexico)
P07: Classifying ovarian masses using ultrasonography
Chairs: W. Froyman (Belgium); A.C. Testa (Italy)
P08: New techniques for the evaluation of the fetal heart
Chairs: A. Gagnon (Canada); J. Huhta (United States)

13:10-14:10 Guideline Hubs
Chinese
Chair: Q. Wu (China)

This is the preliminary program and is subject to change
French recommendations for cell-free DNA  
*Chair: G. Haddad (France)*

**Interactive**  
In conversation with N. Raine-Fenning: fertility

14:15-15:15  
**Interactive Hubs**  
3D: the right modality for the right patients in the right time  
*Chair: S. Tudorache (Romania)*

In conversation with D. Timmerman: the IOTA study and classifying ovarian masses Q&A  
*Chairs: T. Bourne; N. Raine-Fenning (United Kingdom)*

15:20-16:20  
**Interactive Hubs**  
Polish Society  
*Chairs: M. Zimmer; M. Wielgos; W. Rokita (Poland)*

Society of Fetal Medicine  
*Chair: TBC*

**Interactive Hubs**  
In conversation with W.P. Martins: uterine anomalies

*Chair: P. Scrosati (Argentina)*

16:25-17:25  
**Interactive Hubs**  
Intrapartum ultrasound quiz: look at the screen and decide how to deliver the baby!  
*Chairs: T. Ghi; G. Rizzo (Italy); B. Tutschek (Switzerland)*

Ultrasound in labour in a low-resource setting  
*Chairs: T.M. Eggebø (Norway); R. Kamel (Egypt)*

Why 'P' valves are not the be all and end all  
*Chair: L. Wynants (Belgium)*

17:30-18:00  
**New for 2019!**  
Key messages from Monday: Convention Hall II  
*Chairs: L. Drukker (United Kingdom); M. Gil (Spain)*

Key messages from Monday: Convention Hall I (D)  
*Chairs: G. Kasprian (Austria); F. D'Antonio (Norway)*

Key messages from Monday: Estrel Hall (A+B)  
*Chairs: R. Napolitano (United Kingdom); M. Cruz-Lemini (Spain)*

---

This is the preliminary program and is subject to change